Minerva Neurosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Minerva Neurosciences, Inc.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Cyrenaic Pharmaceuticals, Inc.
- Mind-NRG SA
- Sonkei Pharmaceuticals, Inc.